Trial Profile

A phase 2 study of alisertib for the treatment of hormone receptor positive, HER2-negative breast cancer

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 12 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Nov 2024 According to Puma Biotechnology media release, interim data from the study is expected in 2025.
07 Nov 2024 According to Puma Biotechnology media release, initiation of this trial expected in Q4 2024.
11 Dec 2023 According to Puma Biotechnology media release, based on Companys interactions with the U.S. Food and Drug Administration (FDA), the Company will be initiating a Phase II trial of alisertib in combination with endocrine treatment in second half of 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com